PURE Bioscience (NASDAQ: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the second fiscal quarter ended January 31, 2013.
Revenues for the second fiscal quarter of 2013 were $263,000, compared with revenues of $221,000 for the second fiscal quarter of 2012.
